Bend Research announces new facility
Bend Research Inc., a leading independent drug-formulation development and manufacturing company, announced Wednesday the addition of a new current Good Manufacturing Practice spray-drying facility.
The new facility expands Bend Research’s state-of-the-art capabilities and expertise in the area of development and manufacture of high-potency drug candidates.
The company’s new facility is well-suited for the manufacture of a wide range of compound types and safety classifications, ranging from inhalable biotherapeutics to oral solid form high-potency small molecules.
The facility is physically separated from the company’s other development and cGMP manufacturing facilities and is designed for high containment operations at the highest safety and quality standards, utilizing the latest best-practice design features, finishes and engineering controls at the equipment level.
“We’re excited to offer our clients expanded cGMP spray-drying capability for high-potency compounds,” said Rod Ray, Chief Executive Officer. “This facility will complement our small molecule cGMP spray drying capabilities.”
The new facility is only part of the Bend Research’s expansion plans as the company enters its next phase of strategic growth. In addition to the new high-potency spray-drying facility, the company recently expanded its solid-dosage-form capability and purchased an additional building for future expansion of development and manufacturing capabilities.
For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems.
This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.
Bend Research capabilities include formulation and dosage-form support, process development and optimization, manufacture of clinical-trial quantities of drug candidates in its cGMP facilities, and advancement of promising drug candidates from conception through commercialization.
Bend Research is a leader in novel formulations, including spray-dried dispersions (SDDs) and hot-melt extrusions, and controlled-release, inhalation, and biotherapeutics technologies. Bend Research has more than 285 employees based in six state-of-the-art facilities in Bend, Oregon.
